Composition useful as anticancer drug and radiosensitizer
AssigneePHARMGENIA CO., LTD. of Developmental Genetics Laboratory,
InventorsJong-Kuk Park, Young-Do Yoo
Life of this patent
Estimating the term…
Abstract
The present invention relates to the novel use of the compound [N′-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester] as an anticancer agent. The present invention also relates to the novel use of the compound [N′-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester] in combination with radiotherapy for enhancing radiotherapy on cancerous cells or tumors.
Claims13
A pharmaceutical composition useful for treating cancers in mammals, which comprises the therapeutically effective amount of the compound of formula I and a pharmaceutically acceptable carrier:
- 4
A pharmaceutical composition useful for enhancing radiotherapy on cancers in mammals, which comprises the therapeutically effective amount of the compound of formula I and a pharmaceutically acceptable carrier:
- 5
A method for treating cancers in mammals, which comprises administering the effective amount of the compound of formula I:
- 6
A method for enhancing radiotherapy on cancers in mammals, which comprises administering the effective amount of the compound of formula I in combination with radiotherapy:
- 7
Dependencies are inferred from the claim text.